Leflunomide, a Reversible Monoamine Oxidase Inhibitor

E-ISSN： 1875-6166|16|2|112-119

ISSN： 1871-5249

Source： Central Nervous System Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Central Nervous System Agents), Vol.16, Iss.2, 2016-08, pp. : 112-119

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Effect of the reversible monoamine oxidase-A inhibitor befloxatone on the rat 5-hydroxytryptamine neurotransmission

By Haddjeri N. De Montigny C. Curet O. Blier P.

European Journal of Pharmacology, Vol. 343, Iss. 2, 1998-02 ,pp. : 179-192

Elsevier

Access to resources Recommend Favorite

Pirlindole: A Selective Reversible Inhibitor of Monoamine Oxidase a. A Review of Its Preclinical Properties

By Bruhwyler J. Liegeois J.F. Geczy J.

Pharmacological Research, Vol. 36, Iss. 1, 1997-07 ,pp. : 23-33

Academic Press

Access to resources Recommend Favorite

A reversible monoamine oxidase inhibitor, Toloxatone: comparison of its physicochemical properties with those of other inhibitors including Brofaromine, Harmine, R40519 and Moclobemide

By Moureau F. Wouters J. Depas M. Vercauteren D. Durant F. Ducrey F. Koenig J. Jarreau F.

European Journal of Medicinal Chemistry, Vol. 30, Iss. 11, 1995-01 ,pp. : 823-838

Elsevier

Access to resources Recommend Favorite

Monoamine oxidase inhibitor sensitive site implicated in sensitization to quinpirole

By Culver K.E. Szechtman H.

European Journal of Pharmacology, Vol. 339, Iss. 2, 1997-11 ,pp. : 109-111

Elsevier

Access to resources Recommend Favorite

Reversible inhibition of type B monoamine oxidase. Theoretical study of model diazo heterocylic compounds

By Wouters J. Ooms F. Jegham S. Koenig J. George P. Durant F.

European Journal of Medicinal Chemistry, Vol. 32, Iss. 9, 1997-09 ,pp. : 721-730

Elsevier

Access to resources Recommend Favorite